Zensar Technologies Limited — Important, 25-04-2025: Updates

Zensar Technologies' Board has conducted its latest review, resulting in several significant decisions impacting its financial and operational structures.

**Financial Highlights:** The firm reported robust financial results with total revenue from operations reaching ₹22,261 crore for the financial year ending March 31, 2025, an increase from ₹20,192 crore in the previous year. The company posted a net profit of ₹5,898 crore, showcasing growth from ₹4,790 crore in FY 2024. EBITDA margins reflect strong operational efficacy, registering a healthy growth trajectory.

**Strategic Initiatives and Growth Drivers:** In line with its growth strategy, Zensar has confirmed the appointment of new Secretarial Auditors for a five-year term, enhancing its governance framework. Additionally, the board has proposed a final dividend of ₹11 per equity share, signaling its commitment to return value to shareholders.

**Business Developments:** Zensar’s subsidiary has made strategic moves by acquiring a 100% stake in BridgeView Life Sciences, aiming to bolster its position in the biopharma technology consulting sector. This acquisition aligns with its long-term growth initiatives.

**Market Position and Competitive Advantage:** Zensar continues to solidify its market presence with a diversified service portfolio that strengthens its competitive advantage in the digital transformation space. The firm is well-equipped to leverage ongoing industry shifts toward digitalization.

**Investor Implications:** The proposed final dividend and strong financial performance indicate a positive outlook for Zensar investors. This positions the company favorably for future growth, promising both stability and opportunities as it navigates its strategic objectives.